Toggle navigation
Browse
Home
Researchers
Research Departments
Publications
About/Support
FUTURE ONCOLOGY
Journal
Overview
Identity
Other
View All
Overview
publication venue for
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
2024
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
. 15:2073-2082.
2019
Identity
International Standard Serial Number (ISSN)
1479-6694
Electronic International Standard Serial Number (EISSN)
1744-8301
Other
journal abbreviation
FUTURE ONCOL